Pacific Biosciences Of California (PACB) Accumulated Expenses (2010 - 2026)

Pacific Biosciences Of California's Accumulated Expenses history runs 17 years deep, the most recent figure standing at $33.9 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 15.57% year-over-year to $33.9 million in Q1 2026; TTM through Mar 2026 was $33.9 million, a 15.57% increase from a year earlier, with the FY2025 full-year figure at $33.6 million, up 48.91% from the prior year.
• Accumulated Expenses climbed to $33.9 million in Q1 2026 per PACB's latest filing, from $33.6 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $45.7 million in Q4 2023 and bottomed at $19.2 million in Q3 2024.
• The 5-year median for Accumulated Expenses is $26.5 million (2025), against an average of $27.5 million.
• Across the five-year window, Accumulated Expenses tumbled 50.57% in 2024 and jumped 52.07% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $32.6 million in 2022, then soared by 40.23% to $45.7 million in 2023, then tumbled by 50.57% to $22.6 million in 2024, then soared by 48.91% to $33.6 million in 2025, then advanced by 0.77% to $33.9 million in 2026.
• Per Business Quant, the three latest PACB Accumulated Expenses figures stand at $33.9 million (Q1 2026), $33.6 million (Q4 2025), and $29.2 million (Q3 2025).